The "Coiled Spring" Effect: Why Nephro Care India (NCIL) Is Poised for a Valuation Re-Rating
While the market fixates on suppressed trailing margins, the "J-Curve" of operating leverage and high-value transplants is setting the stage for a profit breakout in H2 FY26.
If you’ve been following my Substack for a while, you know I have a soft spot for business models with high “operating leverage”—businesses where a small increase in revenue leads to a massive jump in the bottom line.
Lately, I’ve been digging into Nephro Care India Limited (NCIL). After parsing through their August 2025 investor presentation and FY25 performance, I’ve realized that the market might be missing a massive “inflection point” coming in the second half of FY26 (H2 FY26).
Here is the math on why I think the current valuation doesn’t reflect what’s coming.
To understand more about the business you can go through - (Or you can skip as well)
The “H2 FY26” Inflection Point
To understand NCIL, you have to look at their Vivacity Hospital in Kolkata. In FY25, the company generated ₹46.03 Crore in revenue for the entire year.
My projections suggest that in H2 FY26 alone (Oct ‘25 – March ‘26), the company could generate between ₹40.5 Crore and ₹45.5 Crore.
The Insight: We are looking at a scenario where NCIL could potentially do an entire year’s worth of FY25 revenue in just six months of FY26.
Breaking Down the Math
Let’s get into the weeds. I’ve broken this down by segment to show you where the growth is coming from.